Article Text

Download PDFPDF

Cryoablation therapy stimulates the antigen-specific T cell immune responses generated by therapeutic HPV DNA vaccine
  1. Sung Yong Lee1,
  2. Kyung Hoon Min2,
  3. Gyu Young Hur2,
  4. Je Hyeong Kim3,
  5. Jae Jeong Shim1,
  6. Kyung Ho Kang1,
  7. Kye Young Lee4,
  8. Chien-Fu Hung5 and
  9. TC Wu5
  1. Aff1 grid.411134.20000000404740479Korea University Medical Center Seoul Republic Of Korea
  2. Aff2 grid.411134.20000000404740479Korea University Medical Center Seoul South Korea
  3. Aff3 grid.411134.20000000404740479Korea University Medical Center Ansan South Korea
  4. Aff4 grid.258676.80000000405328339Konkuk University, School of Medicine Seoul South Korea
  5. Aff5 grid.21107.350000000121719311Johns Hopkins Medical Institution Baltimore MD USA

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Meeting abstracts

Antigen-specific DNA vaccine immunotherapy is an attractive approach for the treatment of cancer since it has the potency to specifically eradicate systemic tumors without damaging the normal cells. However, DNA vaccine shows insufficient immune response for antigen presenting cells and has minimal clinical efficacies. Cryoablation therapy is the therapeutic application of extreme cold for localized destruction of living tissue. It can develop cancer cell necrosis and release damage-associated molecular patterns (DAMPs) in tumor microenvironment. According to other reports, cryotherapy has immunogenic potential. Therefore, we explored the employment of cryoablation in combination with HPV E7 specific CRT/E7 DNA vaccine in a preclinical mouse model. For in vivo experiment, the mice were divided into four groups: group 1 received no treatment after the E7-expressing TC-1 tumor challenge, group 2 was treated with cryoablation therapy, group 3 was immunized with the CRT/E7 DNA vaccine, and group 4 was both immunized and received cryoablation therapy. Mice were monitored for E7-specific CD8 (+) T cell immune responses, myeloid-derived suppressor cells (MDSCs) and antitumor effects. In vitro assay, TC-1 cells were incubated in deep freezing and thawed for determination of HMGB1 from the supernatant. The combination therapy of cryoablation and CRT/E7 DNA vaccination significantly inhibited tumor growth and increased E7-specific CD8+ T cells in spleen compared to other treatment groups. Furthermore, the immunosuppressive MDSCs in tumor mass were significantly decreased in combination therapy group. We found that treatment with deep freezing and thawing led to up-regulation of HMGB1 in TC-1 tumor cells, rendering the tumor cells more susceptible to APCs and E7-specific CD8+ T cell-mediated killing. In conclusion, cryoablation therapy can enhance therapeutic HPV DNA vaccine potency in generating improved antigen-specific immune responses and antitumor effects through the DAMP signal. These findings have important implications for future clinical translation.